Avidity Partners 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 61 US equity positions worth $1.0bn in its Q4 2024 13F filing. The largest position was DNTH at 6.2% of the reported book, followed by BSX and JANX. Against the Q3 2024 filing, it opened 3 new positions, added to 6 and reduced 40 among the top 50 holdings.
What did Avidity Partners own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 6.2% | $62.6m | 2,873,000 | -2% | reduced |
| 2 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.6% | $46.0m | 515,000 | -46% | reduced |
| 3 | JANX JANUX THERAPEUTICS INC | Healthcare | 4.0% | $39.7m | 741,900 | 32% | added |
| 4 | NTRA NATERA INC | Healthcare | 3.5% | $35.4m | 223,800 | -60% | reduced |
| 5 | EXK EXACT SCIENCES CORP | Basic Materials | 3.4% | $33.9m | 603,011 | 3% | added |
| 6 | ISRG INTUITIVE SURGICAL INC | Healthcare | 3.4% | $33.8m | 64,800 | -56% | reduced |
| 7 | CGON CG ONCOLOGY INC | Healthcare | 3.1% | $31.5m | 1,097,800 | -34% | reduced |
| 8 | UNH UNITEDHEALTH GROUP INC | Healthcare | 3.0% | $30.4m | 60,000 | -31% | reduced |
| 9 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.0% | $30.1m | 220,400 | -52% | reduced |
| 10 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.9% | $29.0m | 1,126,700 | -18% | reduced |
| 11 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.9% | $28.9m | 234,500 | -46% | reduced |
| 12 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 2.7% | $27.5m | 666,200 | -9% | reduced |
| 13 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.6% | $26.1m | 658,000 | -33% | reduced |
| 14 | ARVN ARVINAS INC | Healthcare | 2.6% | $26.0m | 1,358,000 | -9% | reduced |
| 15 | GKOS GLAUKOS CORP | Healthcare | 2.5% | $25.5m | 170,000 | -51% | reduced |
| 16 | DXCM DEXCOM INC | Healthcare | 2.5% | $24.7m | 318,000 | 32% | added |
| 17 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.3% | $23.2m | 44,600 | -35% | reduced |
| 18 | HUM HUMANA INC | Healthcare | 2.3% | $22.6m | 89,200 | -31% | reduced |
| 19 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.0% | $20.1m | 500,000 | 0% | held |
| 20 | AVTR AVANTOR INC | Healthcare | 2.0% | $20.0m | 947,000 | -23% | reduced |
| 21 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.0% | $19.8m | 1,500,000 | -39% | reduced |
| 22 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.9% | $19.5m | 1,165,800 | -45% | reduced | |
| 23 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.9% | $19.5m | 446,200 | -44% | reduced |
| 24 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.9% | $18.6m | 474,000 | -42% | reduced |
| 25 | THC TENET HEALTHCARE CORP | Healthcare | 1.7% | $17.3m | 137,000 | -46% | reduced |
| 26 | INSM INSMED INC | Healthcare | 1.6% | $16.1m | 232,800 | -61% | reduced |
| 27 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.6% | $15.9m | 188,000 | -37% | reduced |
| 28 | 2655787D BLUEPRINT MEDICINES CORP | 1.5% | $15.4m | 176,600 | -44% | reduced | |
| 29 | DHR DANAHER CORPORATION | Healthcare | 1.5% | $15.4m | 67,000 | -29% | reduced |
| 30 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.5% | $14.8m | 352,000 | -53% | reduced |
| 31 | ILMN ILLUMINA INC | Healthcare | 1.5% | $14.7m | 109,700 | -62% | reduced |
| 32 | ABBV ABBVIE INC | Healthcare | 1.4% | $14.3m | 80,700 | -19% | reduced |
| 33 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.3% | $13.2m | 1,053,300 | 41% | added |
| 34 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 1.2% | $12.2m | 215,000 | -18% | reduced |
| 35 | TMDX TRANSMEDICS GROUP INC | Healthcare | 1.2% | $12.0m | 192,400 | 597% | added |
| 36 | PHAT PHATHOM PHARMACEUTICALS INC | 1.1% | $11.3m | 1,390,100 | -23% | reduced | |
| 37 | SGRY SURGERY PARTNERS INC | Healthcare | 1.1% | $10.9m | 514,200 | -38% | reduced |
| 38 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.0% | $10.2m | 1,265,200 | -13% | reduced |
| 39 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $9.1m | 354,000 | -60% | reduced | |
| 40 | INCY INCYTE CORP | Healthcare | 0.9% | $9.0m | 129,600 | -58% | reduced |
| 41 | CATX PERSPECTIVE THERAPEUTICS INC | 0.9% | $8.6m | 2,694,600 | -22% | reduced | |
| 42 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.9% | $8.5m | 62,000 | -48% | reduced |
| 43 | BHVN BIOHAVEN LTD | Healthcare | 0.8% | $8.3m | 222,900 | -52% | reduced |
| 44 | INTRA-CELLULAR THERAPIES INC | 0.8% | $8.1m | 97,000 | -58% | reduced | |
| 45 | IMUX IMMUNIC INC | Healthcare | 0.8% | $8.0m | 7,966,400 | -4% | reduced |
| 46 | CNTX CONTEXT THERAPEUTICS INC | 0.8% | $7.9m | 7,477,200 | 1% | added | |
| 47 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.7% | $6.8m | 352,124 | -55% | reduced |
| 48 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.6% | $6.0m | 8,400 | – | new |
| 49 | BRKR BRUKER CORP | Healthcare | 0.4% | $4.5m | 76,300 | – | new |
| 50 | VERA VERA THERAPEUTICS INC | Healthcare | 0.4% | $4.2m | 100,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.